A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-20

Study Completion Date

2025-09-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and effect of food on LY4064809 and the safety and effect of stomach changes by a proton pump inhibitor (PPI) esomeprazole, under fasted conditions in healthy adult participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.

NCT03137134

Healthy

COMPLETED PHASE1

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

NCT02023125

Healthy Volunteer

COMPLETED PHASE1

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

NCT00586963

Erosive Esophagitis Reflux Esophagitis GERD

COMPLETED

A Study of Baricitinib and Omeprazole in Healthy Participants

NCT01925144

Healthy Volunteers

COMPLETED PHASE1

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT03849690

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 Treatment A Fasted

LY4064809 administered orally

Group Type EXPERIMENTAL

LY4064809

Intervention Type DRUG

Administered orally

Group 1 Treatment B High-Fat Meal

LY4064809 administered orally

Group Type EXPERIMENTAL

LY4064809

Intervention Type DRUG

Administered orally

Group 2 Treatment A Fasted

LY4064809 administered orally

Group Type EXPERIMENTAL

LY4064809

Intervention Type DRUG

Administered orally

Group 2 Treatment C Proton Pump Inhibitor (PPI) Effect

LY4064809 administered orally with esomeprazole

Group Type EXPERIMENTAL

LY4064809

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY4064809

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are healthy as determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations at screening and/or admission as assessed by the investigator (or designee)
* Participants have normal blood pressure and pulse rate, as determined by the investigator
* Have venous access sufficient to allow for blood sampling
* Have a body mass index (BMI) within the range 18-32 kilogram/square meter (kg/m²) (inclusive)
* Individuals not of childbearing potential and individuals assigned male at birth may participate in this trial

Exclusion Criteria

* History or presence of any of the following conditions, deemed clinically significant by the investigator (or designee), which may significantly alter the absorption, metabolism, or elimination of drugs, constitute a risk when taking the study intervention or interfere with the data interpretation:

* Metabolic disease, including congenital non-hemolytic hyperbilirubinemia (for example, Gilbert syndrome),
* Biliary disease, including cholecystectomy,
* Gastrointestinal (GI) disease,
* Hematological disease,
* Neurological disease,
* Significant history of, or presence of hepatic disease, including any abnormal liver function tests and serum total bilirubin above the 1.5

× upper limits of normal (ULN) range per the laboratory's reference ranges at screening or admission, or
* Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of LY4064809
* History of a major surgical procedure within 30 days prior to screening
* Diagnosed and/or treated malignancy within 5 years prior to screening with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and curatively resected in situ carcinoma of the cervix.
* Have known allergies to LY4064809 or related compounds or esomeprazole or related compounds

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes